On June 30, CSPC Pharmaceutical fell 3.08% in regular trading, trading at HK$6.93/share, with turnover of HK$481 million. The decline comes amid uniform weakness across the pharmaceutical sector, with peers including Asymchem down 8.97%, Luye Pharma down 6.38%, Hansoh Pharma down 3.23%, and Hengrui Pharma down 2.15%.

Notably, the stock had surged over 10% in the prior session after announcing that its core ADC drug SYS6010 in combination with enlonstobart had officially commenced a Phase III clinical trial in China for the treatment of driver-gene-negative non-small cell lung cancer, with the first subject enrollment planned for July. Today's retreat partially reflects profit-taking pressure following that sharp rally, compounded by sector-wide headwinds.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)